Form 4: Pfizer Director Cyrus Taraporevala Reports Acquisition of Phantom Stock Units
SEC Form 4 Filing
Director Cyrus Taraporevala reports acquisition of phantom stock units representing deferred director's compensation.
Summary
- On September 30, 2024, Cyrus Taraporevala, a director of Pfizer Inc., acquired 1,295.784 phantom stock units.
- These units represent deferred director's compensation, including dividend equivalents.
- The units will be settled in cash or common stock at the director's election following retirement from the Board of Directors.
- The price of the underlying common stock was $28.94.
- Following the transaction, Mr. Taraporevala directly owns 7,547.431 derivative securities.
Sentiment
Score: 7
Explanation: The sentiment is neutral as it reflects a standard transaction related to director compensation. There are no indications of positive or negative implications for the company's performance.
Future Outlook
The phantom stock units will be settled in cash or common stock at the director's election following retirement from the Board of Directors.
Industry Context
This filing is a routine disclosure related to director compensation and is typical for publicly traded companies. It provides transparency into the equity-based compensation of Pfizer's directors.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding director compensation.
Key Dates
| Date | Description |
|---|---|
| 09/30/2024 | Date of transaction: Acquisition of phantom stock units. |
| 10/02/2024 | Date of report filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.